ArticlePloS one2026
Diagnostic performance of DNA index for detection of high hyperdiploidy in childhood B-cell acute lymphoblastic leukemia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh hyperdiploidy (HHD) is the most common cytogenetic abnormality in childhood B-cell acute lymphoblastic leukemia (B-ALL) and is a pivotal finding for prognosis evaluation and treatment stratification. Karyotyping is considered the gold standard for detecting HHD; however, cytogenetic cultures sometimes fail. The DNA index (DI) analysis by flow cytometry (FCM) is a quick and simple approach to estimating HHD without the need for cultures. The aim of this study was to assess the diagnostic performance of DI for detecting HHD in pediatric patients with B-ALL.
methodsA cross-sectional study was conducted on 210 pediatric patients with B-ALL at Instituto Nacional de Salud del Niño San Borja (INSNSB) in Peru between 2017 and 2021. The receiver operating characteristic (ROC) curve was analyzed using karyotype results as the reference standard to determine the optimal DI cut-off value for HHD. The main diagnostic performance indicators were subsequently described. Immunophenotypic characteristics associated with HHD were also explored using a generalized linear model (GLM).
resultsA 25.2% (n = 53/210) rate of failed karyotypes was observed. DI ≥ 1.10 showed a sensitivity of 96.6% (95% CI: 93.7-99.4%), specificity of 89.8% (95% CI: 85.1-94.6%), positive predictive value of 68.3% (95% CI: 61.0-75.6%), negative predictive value of 99.1% (95% CI: 97.7-100.0%), and AUC of 0.947 (95% CI: 0.914-0.980). The overall concordance between DI and karyotype was 91.1% (n = 143/157), with a Kappa index 0.75 (95% CI: 0.62-0.87). Blast size (PR = 4.8, 95% CI: 2.7-8.5) and CD123 expression (95% CI: 1.9-73) were associated with HHD (p < 0.001 and p < 0.009, respectively).
conclusionDI has a high diagnostic performance and is helpful as a complementary method to karyotyping for detecting HHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.